Top Markets
#1 Purr Purr +65.71%
#2 Pons Pons +57.23%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 Non-Playable Coin Non-Playable Coin +35.41%
#5 ApeX ApeX +27.63%
#6 Kinetiq Kinetiq +25.02%
#7 Morpho Morpho +24.89%
#8 TENDIES TENDIES +23.19%
#9 StonkBroker StonkBroker +21.13%
#10 Cash Cat Cash Cat +20.94%
Coin of the day
Purr Purr
설정
언어
한국어
통화
USD
테마
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
주식 순위 #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
주가
$7.12
마지막 동기화: 2023-03-08
시가총액
$117.03M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
GB
거래 F-star Therapeutics, Inc. (FSTX)

카테고리

Healthcare
F-star Therapeutics, Inc. (FSTX)의 매출
Aug 2026 기준 매출 TTM: 0
F-star Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
F-star Therapeutics, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH